Daniel Tillett Buys 62,631 Shares of Race Oncology (ASX:RAC) Stock

Race Oncology Limited (ASX:RAC) insider Daniel Tillett purchased 62,631 shares of Race Oncology stock in a transaction that occurred on Wednesday, February 11th. The stock was acquired at an average cost of A$2.40 per share, with a total value of A$150,314.40.

Daniel Tillett also recently made the following trade(s):

• On Friday, February 13th, Daniel Tillett sold 14,000 shares of Race Oncology stock. The stock was sold at an average price of A$2.15, for a total transaction of A$30,100.00.
• On Thursday, January 22nd, Daniel Tillett acquired 400,000 shares of Race Oncology stock. The stock was acquired at an average cost of A$1.25 per share, for a total transaction of A$500,000.00.
• On Thursday, December 18th, Daniel Tillett acquired 12,218 shares of Race Oncology stock. The shares were acquired at an average price of A$2.58 per share, with a total value of A$31,534.66.
• On Thursday, December 18th, Daniel Tillett bought 300,000 shares of Race Oncology stock. The shares were acquired at an average cost of A$1.25 per share, with a total value of A$375,000.00.
• On Wednesday, November 26th, Daniel Tillett bought 22,000 shares of Race Oncology stock. The stock was acquired at an average price of A$2.67 per share, for a total transaction of A$58,740.00.

Race Oncology Stock Performance

The stock has a market cap of $211.94 million, a price-to-earnings ratio of -14.60 and a beta of 1.74.

About Race Oncology

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein).